标题/作者	年份
The cytokine storm and COVID‐19 B Hu, S Huang, L Yin Journal of medical virology 93 (1), 250-256	2021
Covid-19 and autoimmunity M Ehrenfeld, A Tincani, L Andreoli, M Cattalini, A Greenbaum, D Kanduc, ... Autoimmunity reviews 19 (8), 102597	2020
Virus-receptor interactions of glycosylated SARS-CoV-2 spike and human ACE2 receptor P Zhao, JL Praissman, OC Grant, Y Cai, T Xiao, KE Rosenbalm, K Aoki, ... Cell host & microbe 28 (4), 586-601. e6	2020
Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes J Van Paassen, JS Vos, EM Hoekstra, KMI Neumann, PC Boot, ... Critical Care 24, 1-22	2020
Pharmaco-immunomodulatory therapy in COVID-19 JG Rizk, K Kalantar-Zadeh, MR Mehra, CJ Lavie, Y Rizk, DN Forthal Drugs 80, 1267-1292	2020
Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad S Ahmed, O Zimba, AY Gasparyan Clinical rheumatology 39, 2529-2543	2020
Cognitive impact of COVID-19: looking beyond the short term S Miners, PG Kehoe, S Love Alzheimer's research & therapy 12 (1), 1-16	2020
Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID‐19: a multicenter retrospective cohort study Z Shao, Y Feng, L Zhong, Q Xie, M Lei, Z Liu, C Wang, J Ji, H Liu, Z Gu, ... Clinical & translational immunology 9 (10), e1192	2020
Fruitful neutralizing antibody pipeline brings hope to defeat SARS-Cov-2 A Renn, Y Fu, X Hu, MD Hall, A Simeonov Trends in pharmacological sciences 41 (11), 815-829	2020
Influenza infection, SARS, MERS and COVID-19: cytokine storm–the common denominator and the lessons to be learned VA Ryabkova, LP Churilov, Y Shoenfeld Clinical Immunology 223, 108652	2021
Nrf2 activator PB125® as a potential therapeutic agent against COVID-19 JM McCord, BM Hybertson, A Cota-Gomez, KP Geraci, B Gao Antioxidants 9 (6), 518	2020
Myocarditis in COVID-19 patients: current problems D Mele, F Flamigni, C Rapezzi, R Ferrari Internal and emergency medicine, 1-7	2021
Revisiting pharmacological potentials of Nigella sativa seed: A promising option for COVID‐19 prevention and cure MN Islam, KS Hossain, PP Sarker, J Ferdous, MA Hannan, MM Rahman, ... Phytotherapy Research 35 (3), 1329-1344	2021
COVID-19-associated opportunistic infections: a snapshot on the current reports A Abdoli, S Falahi, A Kenarkoohi Clinical and experimental medicine 22 (3), 327-346	2022
Multisystem inflammatory syndrome associated with COVID-19 from the pediatric emergency physician's point of view H Simon Junior, TMS Sakano, RM Rodrigues, AP Eisencraft, ... Jornal de pediatria 97, 140-159	2021
Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective C Lee, WJ Choi Archives of pharmacal research 44, 99-116	2021
A review on current repurposing drugs for the treatment of COVID-19: reality and challenges MS Hossen, MA Barek, N Jahan, M Safiqul Islam SN comprehensive clinical medicine 2, 1777-1789	2020
Calming the storm: natural immunosuppressants as adjuvants to target the cytokine storm in COVID-19 AE Peter, BV Sandeep, BG Rao, VL Kalpana Frontiers in pharmacology 11, 583777	2021
Autoimmunity as the comet tail of COVID-19 pandemic R Talotta, E Robertson World Journal of Clinical Cases 8 (17), 3621	2020
Innate lymphoid cell composition associates with COVID‐19 disease severity M García, E Kokkinou, A Carrasco Garcia, T Parrot, LM Palma Medina, ... Clinical & translational immunology 9 (12), e1224	2020

1 - 20

计算机程序会自动估算并确定日期和引用次数。